Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker MXCT
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Douglas J. Swirsky CHIEF FINANCIAL OFFICER | MXCT MaxCyte, Inc. | Sale | 10,142 | $0.82 | $8,316 Sale | Form 4 ↗ |
| Aug 13, 2025 | Douglas J. Swirsky CHIEF FINANCIAL OFFICER | MXCT MaxCyte, Inc. | Buy | 50,000 | $1.29 | $64.5K Buy | Form 4 ↗ |
| Aug 13, 2025 | Maher Masoud President and CEO, Director | MXCT MaxCyte, Inc. | Buy | 75,000 | $1.37 | $102.8K Buy | Form 4 ↗ |
| Aug 13, 2025 | Stanley C. Erck Director | MXCT MaxCyte, Inc. | Buy | 100,000 | $1.37 | $137.0K Buy | Form 4 ↗ |
| Aug 13, 2025 | Richard Douglas Director | MXCT MaxCyte, Inc. | Buy | 80,000 | $1.39 | $111.2K Buy | Form 4 ↗ |
| Aug 13, 2025 | William W. Brooke Director | MXCT MaxCyte, Inc. | Buy | 50,000 | $1.29 | $64.5K Buy | Form 4 ↗ |
| Jun 25, 2025 | Rekha Hemrajani Director | MXCT MaxCyte, Inc. | Sale | 10,684 | $2.09 | $22.3K Sale | Form 4 ↗ |
| Mar 18, 2025 | Ali Soleymannezhad Chief Commercial Officer | MXCT MaxCyte, Inc. | Sale | 1,211 | $3.18 | $3,851 Sale | Form 4 ↗ |
| Mar 18, 2025 | David I. Sandoval GENERAL COUNSEL | MXCT MaxCyte, Inc. | Sale | 353 | $3.18 | $1,123 Sale | Form 4 ↗ |
| Mar 18, 2025 | Douglas J. Swirsky CHIEF FINANCIAL OFFICER | MXCT MaxCyte, Inc. | Sale | 6,939 | $3.18 | $22.1K Sale | Form 4 ↗ |
| Jan 27, 2025 | John Joseph Johnston Director | MXCT MaxCyte, Inc. | Sale | 3,000 | $4.65 | $13.9K Sale | Form 4 ↗ |
| Jan 13, 2025 | David I. Sandoval GENERAL COUNSEL | MXCT MaxCyte, Inc. | Sale | 4,466 | $4.54 | $20.3K Sale | Form 4 ↗ |
| Dec 26, 2024 | John Joseph Johnston Director | MXCT MaxCyte, Inc. | Sale | 3,000 | $4.01 | $12.0K Sale | Form 4 ↗ |
| Dec 9, 2024 | John Joseph Johnston Director | MXCT MaxCyte, Inc. | Sale | 2,495 | $3.79 | $9,456 Sale | Form 4 ↗ |
| Dec 6, 2024 | John Joseph Johnston Director | MXCT MaxCyte, Inc. | Sale | 505 | $3.70 | $1,869 Sale | Form 4 ↗ |
| Nov 1, 2024 | Stanley C. Erck Director | MXCT MaxCyte, Inc. | Sale | 47,689 | $3.72 | $177.4K Sale | Form 4 ↗ |
| Oct 28, 2024 | John Joseph Johnston Director | MXCT MaxCyte, Inc. | Sale | 3,000 | $3.72 | $11.2K Sale | Form 4 ↗ |
| Oct 2, 2024 | Stanley C. Erck Director | MXCT MaxCyte, Inc. | Sale | 21,607 | $3.71 | $80.2K Sale | Form 4 ↗ |
| Oct 1, 2024 | Stanley C. Erck Director | MXCT MaxCyte, Inc. | Sale | 26,082 | $3.78 | $98.6K Sale | Form 4 ↗ |
19 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances